I met Jesus during the Bayer Data Science & Artificial Intelligence, DS&AI, F2F event in Madrid in May 2023. Jesus works at Bayer AG currently as the Head of Business Disruption. If you are into Stranger Things, Breakthrough Innovations, AcceleRed, TeamRed, Science4Berlin, STEM4Health, Hackathons, Biotech, Digital Health, Startups, Entrepreneurship, Intrapreneurship, Web3, Web5, Networking For Health, Science, Technology, Pharma, Exobiology, Space, Science Fiction, Germany, Cuba, you can connect with Jesus in LinkedIn: https://www.linkedin.com/in/yeysus/ Twitter: https://twitter.com/yeysus Meetup: https://www.meetup.com/members/45080772/ Web3: yeysus.eth/.tez/.near Some of his POAPs collections in Welook.io: Bayer: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/1 Corporates: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/2 Animated: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/5 Ladies: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/8 Beautiful: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/9 Great connecting with you!

Nice to meet you!

Given the considerable amount of data that is collected throughout clinical trials, it can be asked if this data can be used to improve our understanding of the trial, regardless of outcome. The radiomics pilot seeks to provide a toolkit that is capable of analyzing the different modalities of information found in clinical trials (genome, gene expression, biomarker, clinical information, and imaging information) to derive insights into why a patient may be responding, or why a clinical trial was unsuccessful. The current efforts have focused on clinical trials in oncology, while collaborating with the RED-ONC function. Overall, the project is in its pilot state, and demonstrating a proof of concept, while documenting many challenges and learnings with the development of such a toolkit. Potential directions that could expand this toolbox include deriving the factors that best predict why a patient would stay in a clinical trial, and providing assistance with patient selection of clinical trials. Other potential directions involve suggesting why a particular trial may have been unsuccessful and providing that information back to the drug development team.

At the Fiesta de las funciones, we celebrated DS&AI's teams, sub-teams and projects in a dynamic, interactive poster session where everyone presented their work, and attendees could collect a POAP (Proof of Attendance Protocol) for each poster they visited, 20 posters and 21 POAPs. The POAPs served as a digital certificate of attendance and allowed attendees to gamify their participation in the event while getting to know a new digital technology. Utility was given to the person that collected the most POAPs, in the form of a prize given at the end of the event. Additionally, at the end of the poster session, there was a quiz that allowed attendees to test their knowledge of the presented posters. This quiz was a fun way to encourage attendees to interact with the posters and learn more about the various data science, ML and AI work currently going on in DS&AI. It was a great opportunity for Bayer DS&AI colleagues to interact and get to know each other and what we do, and to set the foundations for future collaborations. 

Position: Sr. Manager, Value & Insights Team: Value, Engagement & Training (VET) Dep.: Product Owner Hub (POH) Location: Wuppertal, Germany